Kurve Therapeutics was founded by a chronic sinusitis sufferer determined to cure what repeated attempts — and several surgeries — could not.

Through his extensive research and development, his first device was born. Amazed at how it helped his chronic sinusitis after years of suffering, he knew he had to share his invention with the world. He began his research with leading institutions such as Harvard and Johns Hopkins to determine how his device could be used to benefit those suffering from similar conditions, as well as a vast array of other disorders — including those with fewer treatment options.

Nose-to-brain delivery and bypassing the blood-brain barrier (BBB) have long been the elusive “holy grail” for the treatment of CNS diseases. We knew that was our target, but we also wanted to do more than that; we wanted to create a product that would effectively bypass the BBB while still allowing dosage control, with the hope of yielding higher efficacy rates than any other treatment to date.

The first clinical trial where the endpoints were met was with Kurve devices administering insulin nose-to-brain for Alzheimer’s disease. We believe our purpose is to help people, to eliminate suffering — to bring valuable change.

Kurve Therapeutics, Inc. Videos

Marc Giroux, CEO, Kurve Therapeutics - LSI USA `22 Emerging Medtech Summit - Video